Sugi Predict

Sugi Predict / Compounds / SCHEMBL3387378

SCHEMBL3387378

SCHEMBL3387378

COC(=O)c1n[nH]c2cc(-c3cccc(N)c3)ccc12

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDPK1 O15530 1/20 0.60
▸ KDM4E B2RXH2 1/20 0.57
▸ STAT3 P40763 1/20 0.57
▸ HIF1A Q16665 1/20 0.57
▸ AAK1 Q2M2I8 1/20 0.57
▸ JAK2 O60674 1/20 0.46
▸ GSK3B P49841 3/20 0.45
▸ PAK1 Q13153 1/20 0.45
▸ PRKACA P17612 1/20 0.45
▸ PRKACG P22612 1/20 0.45
▸ PRKACB P22694 1/20 0.45
▸ MAP2K4 P45985 2/20 0.44
▸ CDC7 O00311 1/20 0.44
▸ HDAC6 Q9UBN7 1/20 0.44
▸ AURKA O14965 1/20 0.44
▸ PRKAG1 P54619 1/20 0.43
▸ PRKAA1 Q13131 1/20 0.43
▸ PRKAB1 Q9Y478 1/20 0.43
▸ HDAC1 Q13547 4/20 0.43
▸ HDAC2 Q92769 4/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3385023 0.87 KDM4E (0.60) PDPK1KDM4EAAK1JAK2GSK3B
SCHEMBL14574212 0.85 KDM4E (0.63) KDM4ESTAT3HIF1AGSK3BMAP2K4
SCHEMBL3386730 0.84 PDPK1 (0.67) PDPK1AAK1JAK2GSK3BAURKA
SCHEMBL3387632 0.79 PRKAA1 (0.60) KDM4ESTAT3HIF1AJAK2GSK3B
SCHEMBL173308 0.78 KDM4E (0.65) KDM4ESTAT3HIF1AGSK3BCDC7
SCHEMBL12907253 0.76 PDPK1 (1.00) PDPK1KDM4EAAK1JAK2AURKA
SCHEMBL18115988 0.76 USP30 (0.57) KDM4ESTAT3HIF1AGSK3BDYRK1A
SCHEMBL30668641 0.76 USP30 (0.57) KDM4ESTAT3HIF1AGSK3BDYRK1A
SCHEMBL12788089 0.76 KDM4E (0.65) KDM4ESTAT3HIF1AMAP2K4
SCHEMBL3382243 0.75 KDM4E (0.60) KDM4EJAK2GSK3BPRKAG1PRKAA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8754209-B2 Indazole derivatives or pharmaceutically acceptable salts thereof as protein kinase inhibitors for proliferative diseases treatment, and a pharmaceutical composition containing the same as an active ingredient KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2014-06-17 — — US claimed
US-20120130069-A1 NOVEL INDAZOLE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS PROTEIN KINASE INHIBITORS FOR PROLIFERATIVE DISEASES TREATMENT, AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2012-05-24 — — US claimed
CN-102239150-A Novel indazole derivatives or pharmaceutically acceptable salts thereof as protein kinase inhibitors for proliferative diseases treatment, and a pharmaceutical composition containing the same as an active ingredient KOREA INST SCI & TECH 2011-11-09 — — CN claimed
US-8754209-B2 Indazole derivatives or pharmaceutically acceptable salts thereof as protein kinase inhibitors for proliferative diseases treatment, and a pharmaceutical composition containing the same as an active ingredient KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2014-06-17 — — US disclosed
US-8754209-B2 Indazole derivatives or pharmaceutically acceptable salts thereof as protein kinase inhibitors for proliferative diseases treatment, and a pharmaceutical composition containing the same as an active ingredient KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2014-06-17 — — US disclosed
US-20120130069-A1 NOVEL INDAZOLE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS PROTEIN KINASE INHIBITORS FOR PROLIFERATIVE DISEASES TREATMENT, AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2012-05-24 — — US disclosed
US-20120130069-A1 NOVEL INDAZOLE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS PROTEIN KINASE INHIBITORS FOR PROLIFERATIVE DISEASES TREATMENT, AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2012-05-24 — — US disclosed
CN-102239150-A Novel indazole derivatives or pharmaceutically acceptable salts thereof as protein kinase inhibitors for proliferative diseases treatment, and a pharmaceutical composition containing the same as an active ingredient KOREA INST SCI & TECH 2011-11-09 — — CN disclosed
WO-2010064875-A2 NOVEL INDAZOLE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS PROTEIN KINASE INHIBITORS FOR PROLIFERATIVE DISEASES TREATMENT, AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2010-06-10 — — WO disclosed
WO-2010064875-A2 NOVEL INDAZOLE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS PROTEIN KINASE INHIBITORS FOR PROLIFERATIVE DISEASES TREATMENT, AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2010-06-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120130069-A1 NOVEL INDAZOLE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS PROTEIN KINASE INHIBITORS FOR PROLIFERATIVE DISEASES TREATMENT, AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT RAF1, RET, KDR PDPK1 306/4885KDM4E 2828/4885STAT3 804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.